Vancomycin and Novobiocin

Riley, Harris D.

doi:10.1016/s0025-7125(16)32593-7

Cited by 29 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The daily dosages of sulfisoxazole [ 91 ] and novobiocin [ 92 ] are 75–150 mg/kg/day and 15–30 mg/kg/day, while the protein binding rates are 85% [ 68 ] and >90% [ 93 ], respectively, for the treatment of infections in infants. These two antibiotics, although not considered highly bound to plasma protein, significantly upregulate the bilirubin levels and should not be used in infants with hyperbilirubinemia ( Table 1 ) [ 26 , 27 , 102 ]. Furthermore, sulfisoxazole [ 103 , 104 ] and novobiocin [ 105 , 106 ] have also been proven to significantly increase TSB levels in animal studies, among which sulfisoxazole was found to increase free bilirubin levels in human infants [ 107 ].…”

Section: Impact Of Protein Binding Capacity and Daily Dosage Of A Drugmentioning

confidence: 99%

“…Various drugs are commonly administered for the treatment of diseases in neonates. Although most drugs are considered harmless, rare cases of drug-induced hyperbilirubinemia have been reported [ 24 , 25 , 26 , 27 , 28 ]. Kernicterus or bilirubin neurotoxicity may develop after free bilirubin crosses the blood–brain barrier (BBB) [ 24 , 29 , 30 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Protein Binding Capacity and Daily Dosage of a Drug on Total Serum Bilirubin Levels in Susceptible Infants

et al. 2023

View full text Add to dashboard Cite

Hyperbilirubinemia is a common pathological condition in neonates. Free bilirubin can penetrate the blood–brain barrier (BBB), which can lead to bilirubin neurotoxicity. In the context of predicting the risk of bilirubin neurotoxicity, although the specificity and sensitivity of free bilirubin levels are higher than those of total serum bilirubin (TSB), free bilirubin is not widely monitored in clinical practice. The threshold TSB levels at which phototherapy must be administered have been established previously. However, TSB levels are not well correlated with neurodevelopmental outcomes. Currently, TSB levels are commonly used to guide phototherapy for neonatal hyperbilirubinemia. Some clinical drugs can displace bilirubin from its albumin-binding sites, and consequently upregulate plasma bilirubin. Daily dosages play a vital role in regulating bilirubin levels. A drug with both a high protein binding capacity and high daily dosage significantly increases bilirubin levels in infants. Premature or very low birth weight (VLBW) infants are vulnerable to the upregulation of bilirubin levels as they exhibit the lowest reserve albumin levels and consequently the highest bilirubin toxicity index. Because bilirubin is involved in maintaining the balance between pro-oxidant and antioxidant agents, the downregulation of bilirubin levels is not always desirable. This review provides insights into the impact of protein binding capacity and daily dosage of drugs on the bilirubin levels in susceptible infants.

show abstract

Section: Impact Of Protein Binding Capacity and Daily Dosage Of A Drugmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of Protein Binding Capacity and Daily Dosage of a Drug on Total Serum Bilirubin Levels in Susceptible Infants

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Bactericidal blood levels are below 10 µg/ml. 39 A 500 mg IV dose has a peak concentration of 33 µg/ml at 1 minute and a serum half-life of 6 hours. 37 Eighty percent of vancomycin is excreted in the urine.…”

mentioning

confidence: 99%

“…37 Eighty percent of vancomycin is excreted in the urine. 39 Vancomycin is not absorbed from the GI tract 39 and significant blood levels do not occur in anephric patients given vancomycin orally. 40 Intestinal inflammation does cause a small increase in absorption but blood levels are either undetectable or low.…”

mentioning

confidence: 99%

Ototoxicity of Oral Neomycin and Vancomycin

Kavanagh

McCabe

1983

The Laryngoscope

View full text Add to dashboard Cite

In contrast to parenteral neomycin, which may result in severe and progressive ototoxicity, oral neomycin has been widely used for 25 years, and its index of safety has been regarded as high. Ototoxicity is viewed as an uncommon complication of oral neomycin most likely to occur in patients with renal failure or gastrointestinal inflammation. Two cases of ototoxicity resulting from oral neomycin are presented. Serial audiometric and neomycin blood level testing are suggested as a means of auditory monitoring in patients receiving the drug. A review of experience with oral vancomycin indicates that this drug has not been shown to cause ototoxicity.

show abstract

“…Ή βανκομυκίνη δέν διαπερνά τόν φραγμόν άγγείων-έγκεφάλου, έπί μηνιγγίτιδος όμως ανευρίσκεται είς θεραπευτικός συγκεντρώσεις (Riley 1970).…”

Section: βανκομυκίνηunclassified

Μελετη Διεισδυσεως Της Καρβενικιλλινης Τικαρκιλλινης Μεζλοκιλλινης Και Αζλοκιλλινης Εις Το Εγκεφαλονωτιαιον Υγρον Του Ανθρωπου

Αλεξοπουλοσ¹

View full text Add to dashboard Cite

Vancomycin and Novobiocin

Cited by 29 publications

References 19 publications

Impact of Protein Binding Capacity and Daily Dosage of a Drug on Total Serum Bilirubin Levels in Susceptible Infants

Impact of Protein Binding Capacity and Daily Dosage of a Drug on Total Serum Bilirubin Levels in Susceptible Infants

Ototoxicity of Oral Neomycin and Vancomycin

Μελετη Διεισδυσεως Της Καρβενικιλλινης Τικαρκιλλινης Μεζλοκιλλινης Και Αζλοκιλλινης Εις Το Εγκεφαλονωτιαιον Υγρον Του Ανθρωπου

Contact Info

Product

Resources

About